ORIC Pharmaceuticals, Inc. Overview
Pro stress-test →ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of therapies to counter the resistance mechanisms in cancers. The company focuses on developing novel oncology treatments that address key therapeutic resistance pathways across multiple cancer indications.
Strategic Profile
Pro stress-test →ORIC is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Lead candidates include enozertinib (ORIC-114) and rinzimetostat (ORIC-944) in clinical development.
Competitive Landscape
Pro stress-test →ORIC competes in the precision oncology space against larger pharma programs and specialized biotech companies developing targeted cancer therapies. Competitors focus on similar resistance mechanisms and EGFR/HER2-targeted approaches in non-small cell lung cancer and other indications.
Industry Context
ORIC Pharmaceuticals, Inc. operates in Precision Oncology / Clinical-Stage Biopharmaceuticals.
Key facts
Founded: 2014 · Headquarters: South San Francisco, US · Employees: N/A · Revenue: N/A · Market cap: N/A